Abstract
Supportive care and survivorship strategies in the management of head and neck squamous cell carcinoma (HNSCC) revolve around continued collaborative efforts aimed at early identification and intervention for locoregional disease recurrence, second primary malignancy, management of treatment-related side effects, and provision for psychosocial support. Development of evidence-based guidelines and optimization of these strategies is increasingly important in the setting of improved survival of patients with HNSCC because of a variety of diagnostic and therapeutic advances and evolving demographics of HNSCC patient population, specifically, p16-associated oropharyngeal squamous cell carcinoma.